GSK acknowledges Chinese bribery scandal

<p>The share price of GSK is down as a result.</p>

GlaxoSmithKline (GSK) has admitted some of its executives may have broken the law.

The firm stated it takes the accusations of bribery in China very seriously, but the share price of the company still dropped today (July 22nd).

Abbas Hussain, the UK pharmaceutical firm's Asia Pacific business head, said GSK has "zero tolerance" for this behaviour.

The firm's British head of finance in China, Steve Nechelput, has been banned from travelling since the end of June, it was admitted by GSK today.

Mr Hussain, in a statement, said GSK is taking the situation very seriously, with several of the company's employees believed to have been detained.

"Certain senior executives of GSK China who know our systems well appear to have acted outside of our processes and controls which breaches Chinese law," he said.

In the wake of the news, the share price of GSK is down by 1.23 per cent at 16:26 BST, a drop of more than 20 points on the start of the day's trading activity.

Find up to date information on the FTSE 100 and spread betting strategies at City Index

Join our live webinars for the latest analysis and trading ideas. Register now

GAIN Capital UK Limited (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.